Novartis Agrees to Acquire Excellergy for Up to $2 Billion to Bolster Allergy Portfolio with Potential Xolair Successor

on

Novartis has entered an agreement to acquire Excellergy, Inc., a biotech developing next-generation anti-IgE therapies, for up to $2 billion in upfront and milestone payments.124

The lead asset, Exl-111, is a half-life extended, high-affinity anti-IgE antibody in Phase 1 trials, designed to dissociate receptor-bound IgE for faster, deeper suppression of IgE signaling compared to existing therapies like Xolair.123

Exl-111 could complement Novartis' allergy portfolio, including Xolair (which generated $1.7 billion in 2025 sales), targeting food allergy, chronic urticaria, allergic asthma, and potentially pediatric populations.124

The transaction is expected to close in H2 2026, subject to regulatory approvals and customary conditions.14

Fiona Marshall, President of Biomedical Research at Novartis, stated the acquisition strengthens their allergy leadership with innovative anti-IgE science.12

Sources:

1. https://www.novartis.com/news/media-releases/novartis-agrees-acquire-excellergy-inc-building-allergy-leadership-next-generation-anti-ige-innovation

2. https://www.fiercebiotech.com/biotech/novartis-pens-2b-deal-allergy-biotech-potential-xolair-successor

3. https://www.biopharmadive.com/news/novartis-excellergy-allergy-drugs-deal-xolair/815956/

4. https://www.bioxconomy.com/partnering/big-bucks-for-better-breathing-novartis-to-acquire-excellergy-for-up-to-2bn